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Inheritance of mutations in the V2 receptor gene in thirteen families
with nephrogenlc diabetes Insipidus. Congenital nephrogenic diabetes
insipidus (ND!) is an X-linked recessive disease characterized by
insensitivity of the distal nephron to the antidiuretic effect of arginine
vasopressin. The hypothesis that the defect underlying NDI might be a
dysfunctional renal vasopressin V receptor has recently been proven
by the identification of mutations in the V2 receptor gene in ND!
patients. We examined thirteen unrelated Dutch ND! families and
identified thirteen distinct and unique mutations. These included nine
missense mutations, two nonsense mutations and two small deletions
and were found in the extracellular domains II, ifi and IV, the
intracellular domains!! and IV and in the transmembrane loops I, II, IV
and V of the vasopressin type 2 receptor. In the families with multiple
NDI patients the mutated gene cosegregated with the disease. Our data
suggest a higher mutation frequency in male than in female gametes. No
discrepancies between carrier detection by means of DNA analysis with
closely linked polymorphic markers and the definite diagnosis based on
sequencing data were found.
Congenital nephrogenic diabetes insipidus (NDI) is mostly an
X-linked recessive disease, characterized by renal resistance to
the antidiuretic effect of arginine vasopressin. The disorder
becomes manifest early in infancy with polyuria, periods of
life-threatening dehydration, fever, anorexia, vomiting and fail-
ure to thrive. Without treatment, mental retardation may de-
velop probably due to brain dehydration. Until recently, the
molecular basis underlying ND! was unknown. The neuro-
hypophyseal hormone arginine vasopressin (AVP) exerts its
physiological effects through stimulation of at least two distinct
(i-protein-coupled receptors, vasopressin V1 and V2 receptors
[1]. The vascular V1 receptor, which is connected to a phos-
phoinositide specific phospholipase and Ca2 mobilization,
mediates vasoconstrictor and glycogenolytic responses; the
renal tubular V2 receptor, which is connected to the membrane-
bound adenylate cyclase and stimuiation of cyclic AMP, medi-
ates the antidiuretic response to vasopressin.
In addition to mediating antidiuresis, an apparent V2 medi-
ated action of AVP and its V2-specific agonist, l-desamino-8-
D-arginine vasopressin (DDAVP), causes release of coagulation
and fibrinolytic factors (2] and vasodilation [3]. These extra-
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renal responses are also absent in NDI patients [4—6], suggest-
ing that the defect in this disorder might be a dysfunctional or
nonfunctional vasopressin V2 receptor.
In the last five years the understanding of the genetics and
pathogenesis of X-linked ND! has expanded considerably. The
beginning of the era of studying NDI was marked by the
localization of the disease gene to the distal region of the X
chromosome long arm, to Xq28 [7, 8]. The next step was the
discovery of functional vasopressin V2 receptor activity in
somatic cell hybrids that carried at least the terminal region of
the human X chromosome (Xqter) [9, 10]. This finding sup-
ported the assumption that the ND! gene and the vasopressin
V2 receptor gene might be identical. Very recently, the cloning
of the V2 receptor gene from human [11] and rat [121 was
reported. The V2 receptor gene encodes a G-protein coupled
receptor protein containing seven putative transmembrane he-
lices with considerable sequence homology to the V1 vasopres-
sin and oxytocin receptors.
Definite proof for a vasopressin V2 receptor defect being the
cause of ND! was obtained with the identification of mutations
in the V2 receptor gene in ND! patients [13—18].
In this article we report mutations in the V2 receptor gene in
13 Dutch NDI families. The implications for genetic counseling
are discussed.
Methods
Study subjects
Thirteen ND! families from the Netherlands were included in
the study. All patients were males, eight of them being sporadic
cases, whereas in five families transmission was compatible
with X-linkage. Diagnosis of ND! was based on clinical symp-
toms and lack of increase of urinary osmolality after adminis-
tration of the synthetic vasopressin analogue DDAVP. Maximal
urine osmolalities that could be achieved after DDAVP infusion
were 51 to 198 mOsmollkg (normal.> 805 mOsmol/kg).
DNA analysis
Procedures for the isolation of genomic DNA from patient
blood cells as well as Southern blotting analysis have been
described elsewhere [7, 81. The additional markers tested were
an MspI polymorphism at the locus DXS3O4 [19], a BstYI
polymorphism at the locus DXS455 [20], a TaqI polymorphism
at the locus DXS3O5 [21], an MspI polymorphism at locus
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Table 1. Mutations in the V2 receptor gene in 13 unrelated families
with nephrogenic diabetes insipidus—
.
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Family
DNA
mutation
Mutation at the
protein levela Domainb
029/ND C337T ArgII3Trp ElI
018/ND C6IIA Thr2O4Asn Elil
070/ND T617A Val2O6Asp Eli!
362/ND C541T Argl8lCys Eli!
763/ND 906de11 frameshift EIV
024/ND 457del7 frameshift CII
023/ND CIOO9T Arg337STOP CIV
027/ND C130T Leu44Phe TM1
982/ND T185C Leu62Pro TM1
025/ND G253A Asp85Asn TM2
456/ND G262A Val88Met TM2
046/ND C500T Serl67Leu TM4
013/ND C673T G1n225STOP TM5
a Amino acid numbering according to Birnbaumer et al [11]b Abbreviations are: E, extracellular domain; C, intracellular do-
main; TM, transmembrane region of the proposed topology of the V2
receptor protein [11, 12]
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Fig. 1. Map of the X chromosome showing the position of the Xq28
markers used in this study in relation to the position of the NDJ/V2
receptor gene. The order of loci is derived from the latest X chromo-
some workshop report [24]. Abbreviation is AVPR2, vasopressin V2
receptor gene.
DXS7O7, an EcoRl polymorphism at the DXS6O5 locus [22],
and a CA repeat at the F8 locus [23]. The allele sizes of most of
these polymorphisms are listed in the last Human Gene Map-
ping report [24] and the localization of the markers with respect
to the ND! locus is depicted in Figure 1. Direct automated DNA
sequence analysis on both strands of genomic patient DNA was
performed as described previously [17].
Results
The mutations in V2 receptor gene found in the probands of
each family are shown in Table 1. Thirteen distinct mutations
were identified: two small deletions, two nonsense mutations
and nine missense mutations. These mutations are not clustered
in one domain of the V2 receptor protein but are found
throughout almost the whole receptor, in the extracellular
domains II, III, and IV, the intracellular domains II and IV, and
the transmembrane loops I, II, IV, and V. Mter the mutation in
the affected probands in each family had been characterized,
other family members were screened either by restriction
enzyme analysis (for example, family 024/ND, Fig. 2) or, when
this was not possible by direct sequencing of genomic DNA. In
each of the five families with multiple NDI patients, the
mutation identified in the proband was found in all other
patients but not in the unaffected males of that particular family.
In seven families NDI was due to a de novo mutation. By
combining haplotypes of DNA markers flanking the vasopressin
receptor gene with mutation data in each of these seven
families, the origin of the mutation was deduced in six of them.
In four families the mutation occurred most likely during male
Fig. 2. Segregation of a point mutation in the V2 receptor gene in
family 024/ND followed by restriction enzyme digestion. The mutation
found in the proband resulted in the loss of a BsrI site. The region
around the mutation was amplified with the primers 5'TGGCTCTGT-
TCCAAGTGCTG3' (position 263-282 [11]) and 5'CAGGTGACATAG-
GTGCGACG3' (position 603-623 [11]). PCR was performed as descibed
previously [17]. The PCR product was digested with BsrI and the
fragments were resolved on a 3% agarose gel and stained with ethidium
bromide. For the mutant allele the PCR product of 360 bp was not
cleaved by BsrI, while the wild type allele gave two fragments. The
sizes of the PCR fragments as deduced by comparison with DNA
fragment length standards (not shown) were in agreement with the sizes
predicted on the basis of the published V2 receptor eDNA sequence.
The mother of the patient shows three bands, indicative for heterozy-
gosity. In the lanes of the PCR fragments of the wild type alleles a very
faint band at the position of the uncleaved PCR product is still visible,
which is of no significance. Solid symbol represents the affected
individual.
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Fig. 3. Pedigrees of seven families with
nephrogenic diabetes insipidus (ND!), in
which ND! appeared to be due to a new
mutation. Pedigrees 023/ND, 024/ND, 027/
ND, and 046/ND have been published before
in less detail (7, 8]. Indicated are the alleles
for the DNA markers DXS3O4 (pU6.2: B,b),
DXS455 (p346.72:M,m), DXS3O5 (pSt35.69:
F,f), DXS52 (pStl4: 1,2,3,4,5,6), DXS15
(pDX13: D,d), DXS7O7 (p2-55; G,g), CB
(phs7:H,h), DXS6O5 (p2-19:A,a), and F8
disease is associated with the 1-d-H-E
b B haplotype in pedigree 024/ND, with the b-6-H-
E haplotype in pedigree 023/ND, with the m-6 5 F-2-A haplotype in pedigree 018/ND, with the
— — B-2-g-a-e haplotype in pedigree 362/ND, with
the D-E haplotype in pedigree 027/ND, with
the 1-A2 haplotype in pedigree 456/ND andE e with the 2-e haplotype in pedigree 046/ND.
The segregation of the mutation in the
vasopressin V2 receptor gene (AVPR2) in
each family is depicted by — for the normal
allele and + for the mutant allele. Solid
III
symbols represent affected individuals and
obligate carriers are indicated by a dot in the
symbol; n.t is not tested.
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meiosis: during spermatogenesis in the maternal grandfather in
three families (Fig. 3 a,b,c) and in the maternal great-grandfa-
ther in one family (Fig. 3d). In two families the mutation arose
during female meiosis: during oogenesis in the mother in one
family (Fig. 3e) and in the maternal grandmother in the other
family (Fig. 30. In family 046/ND (Fig. 3g) the origin of the
mutation could not be determined, either during spermatogen-
Fig. 3. Continued
esis in the maternal grandfather or during oogenesis in the
maternal grandmother.
Discussion
The assumption that the NDI gene might be identical to the
vasopressin V2 receptor gene has recently been confirmed by
the identification of several mutations in the V2 receptor gene in
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patients [13—18]. In an affected male of one of their ND!
families, Rosenthal et a! [13] found a deletion in the open
reading frame of the V2 receptor gene causing a frame shift and
premature termination of translation in the third intracellular
domain of the receptor protein. In a patient from another family
the same group detected a point mutation giving rise to an
amino acid substitution in the third transmembrane loop and
causing a change in the hydropathy pattern of the receptor. Pan
et al [14] reported six unique mutations in the V2 receptor gene
of five unrelated NDI patients with one patient having two
mutations. In the latter patient a point mutation causing an
Arg-188-Cys missense mutation and a 1 bp deletion was found.
Very recently, three other groups published distinct defects in
the V2 receptor gene in patients with NDI [15, 16, 18]. In a
previous report [17] we have described the identification of
point mutations in three of our ND! patients. These mutations
resulted in non-conservative amino acid substitutions in the
strongly conserved third extracellular domain of the receptor
protein.
In the present study we have examined the inheritance of
mutations in the V2 receptor gene in 13 additional Dutch
unrelated ND! families. The mutations identified in the 13
probands are unique and include two small deletions, two
nonsense mutations, and ten missense mutations and were
found in the extracellular domains II, III and IV, the intracel-
lular domains II and IV and in the transmembrane loops I, II,
IV, and V. In the families with multiple NDI patients the
mutated V2 receptor gene cosegregated with the disease. The
finding of diverse mutations indicates that ND! is heteroge-
neous at the molecular level, as expected for a typical X-linked
disorder with reduced reproductive fitness in affected males.
After the identification of closely-linked polymorphic DNA
markers [7, 8] in 1987, the carrier status in females at risk could
be determined by DNA linkage analysis. The reliability of this
method depends upon the genetic distance between the markers
and the mutation causing the disease. Although the recombina-
tion frequency between the available DNA markers and the
NDI gene is very low [10], linkage analysis can never establish
a diagnosis with absolute certainty. A 100% accurate diagnosis
is now possible with direct mutation analysis. In this study no
discrepancies were found between the carrier status determined
by linkage analysis and the definite diagnosis based on sequenc-
ing data.
In seven families (pedigrees 018, 023, 024, 027, 046, 362, and
456), it was demonstrated that ND! was due to a de novo
mutation. In six of these cases the patients' mother was shown
to be a gene carrier; thus in these families the mutated gene
originated from the maternal (great)grandparents. In one family
(pedigree 046) it was not possible to deduce the origin of the
mutation. Remarkably, in only one of the other five families
(pedigree 456) the mutation appeared to be on the X chromo-
some that was derived from the maternal grandmother. In the
other cases the mutated gene was shown to be on the X
chromosome that came from either the maternal grandfather
(pedigree 018, 023, 024) or from the maternal great-grandfather
(pedigree 362). Although these numbers are small, they are
consistent with the theory that the mutation rate in the male
germline might be higher than in female germline [25—27]. Direct
mutation analysis of a large number of families with isolated
cases of NDI is necessary to define the exact mutation fre-
quency for ND! in male and female gametes. Knowledge of the
sex ratios of mutation frequencies has implications for genetic
counseling in families with isolated cases. If the mutation
frequency is indeed higher in males than in females, a high
proportion of the mothers of isolated patients will be carriers of
the gene.
In summary, we identified thirteen distinct and unique muta-
tions in thirteen unrelated ND! families. Our data suggest the
possibility of a higher mutation frequency in males than in
females, and underscore the reliabilty of linkage analysis for
heterozygote detection in NDI.
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